2013 Global Medical Devices Outlook

  • July 2013
  • -
  • Frost & Sullivan
  • -
  • 62 pages

Positioning for the Future

This 2013 Frost & Sullivan outlook study provides projections for the global medical devices market. Specifically, the research included identifies market sectors and sub-sectors poised for expansion; discusses key opportunities in emerging markets; identifies the four Rs in the medical device spectrum; and covers strategies for success in the new market paradigm. A timeline of the future of medical technology development is included as are the competitor landscape and a critical country analysis as well as the impact of technology trends. Final thoughts include new marketplace strategies for success and implications for organizations in this industry.

Top-five Growth Sectors

Structural Heart
New technologies, including transcatheter valves and congestive heart failure products, are poised to expand access of care to high-risk patients, who otherwise had no options.

Robotic Assistance
Higher levels of specialty training, coupled with newer and more advanced solutions, are expected to bolster growth in robot-assisted technologies for surgery and treatment planning.

Infection Control Tools
The attention paid to hospital acquired infections (HAI) and associated costs continues to intensify the market appetite for new tools and systems for reducing occurrences.

Home Care
Wellness initiatives, remote monitoring tools, and a push to extend care outside of hospital walls are spurring rapid advancement in novel medical products that can be used in home care settings.

Neuro-devices
Significant expansion of interventional and implantable medical devices to treat brain disorders is expected as new technologies are able to advance care beyond current standards.

Top-five Technology Trends

Interoperability
The rise of new technologies capable of integrating medical devices into a connected platform enhances the functionality of devices, reduces man power burden, and minimizes errors.

Multi-functional
Due to price sensitivity and availability of floor space, highly-specialized pieces of equipment are losing out in purchase decision making to versatile systems capable of addressing multiple needs.

Big Data
The amount of health care data being captured due to recent IT infrastructure upgrades is expected to greatly enhance ‘smart’ and AI functionality for diagnostic and treatment devices.

Low-cost Alternates
Cost-containment initiatives are spurring new types of innovation in medical technologies that provide comparable diagnostic and therapeutic utility at fractions of the cost.

Nano-technology
Nanotechnology provides the benefits of biocompatibility and functionality at an unparalleled scale, allowing it to be better able to influence diseases happening at a cellular level.

Five Companies to Watch in 2013

Johnson & Johnson
Major restructuring of the company in 2012 introduced a new CEO and the consolidation of multiple device franchises into three units. Aggressive portfolio management is expected in 2013 as it sheds sluggish businesses and enters into new markets via acquisitions.

Medtronic
Medtronic’s 2012 Kanghui acquisition exemplifies the emphasis of emerging markets in the company’s long term vision. In the US, expected 2013 approvals for transcatheter and renal denervation technologies would provide access to two hot-growth treatments.

Stryker
In early 2013, Stryker announced acquisition of a Chinese orthopedic implant developer. Value-based devices and access to emerging markets are increasingly driving industry M&A activity. Stryker is also expected to make a play in robot assisted surgery as well.

Covidien
Covidien has been steadily building its portfolio of products via acquisitions to transition from commoditized markets to those with significant growth potential. Now that it has established a presence, the company is expected to be much more aggressive in capturing share.

St. Jude Medical
While St. Jude Medical faces weakening sales for its core markets of pacemakers, ICDs, and artificial heart valves, it is well-positioned in the hot-growth markets of transcatheter valves, fractional flow reserve (FFR) testing, cardiac ablation, neuromodulation, and renal denervation.

CEO’s Perspective

1. Cutting costs and internal resource management are more critical to market viability than a growing top line.
2. Shifts in healthcare spending change the factors impacting market traction making innovation necessary.
3. Overhaul sales strategies to optimize for a consolidated customer base are driven by outcomes and value.
4. Maximizing emerging market strategies are achieved by targeting regions and cities, not countries.
5. The role of the patient is more important in determining treatment and burden of pay for healthcare services.

Three Big Predictions for 2013

1. A hyper-pressurized, cost-containment environment will likely accelerate cost-cutting measures from companies adjusting to the realities of the new marketplace.
2. Patient influence in treatment selection is magnified due to increasing access to information and greater shifts in financial burden. The launch of health exchanges and rollbacks in employer-covered plans could lead to more distinct tiers of coverage.
3. Emerging market needs drive decision making for companies regarding mergers and acquisition (M&A) strategy and product development. With financial resources and on-the-ground infrastructure previously required, companies found it difficult to fully invest in emerging market strategies.

Medical Devices Market Outlook

2012 was a year of transition for the industry as a number of macroeconomic and regulatory events came to a head. The industry essentially closed the chapter on a market era, starting in the mid 1990s that included an explosion of new technologies, advances in care, and significant market expansion. In that time period, with the majority of growth occurring in established markets of the US, Western Europe, and Japan companies were easily able to focus and funnel resources. For an industry tied to government spending for a significant portion of services that unbridled growth quickly becomes unsustainable. As historic demand for services were compounded with higher costs of care per service, the market quickly hit a saturation point that led to reimbursement caps in the US, and austerity measures in Europe.

Looking forward, 2013 seems to be the beginning of a new era in the marketplace that is more sensitive to the value of care. Historically, the market needle was tied nearly exclusively to the launch of new and groundbreaking products that could advance current treatment paradigms. While the opportunities for those sorts of developments still exist, the threshold has shifted for what constitutes an advancement in the market is willing to justify increased spending for. Due to continued pricing pressure, profitability will depend on more sophisticated market strategy related maneuverings to position product offerings for value-conscious consumers.

Market Forecast Discussion

Market forecasts for the medical technology market can vary greatly depending on segmentation. Frost & Sullivan projects a base year market estimate of the global medical technologies market at $X billion, with an end of forecast period projection of $Xbillion in 2017.

Therapeutic medical devices, which make up the primary focus of this outlook, account for approximately X% of the total aggregate medical technologies market. Other segments of the market include diagnostic tools, patient monitoring equipment and supplies, and advanced medical imaging equipment and accessories.

The market witnessed a slowdown from 2008–2011, triggered by the economic recession, which resulted in cost-containment measures in the US, austerity measures in Europe, and market stagnation in Japan. Those pressures are unlikely to ease in the near term. While there are opportunities for certain new treatments, most mature markets could see a gradual decline as reimbursement cuts are enacted.

Growth strategies in emerging markets have proven critical to long-term success for most upper-tier medical device manufacturers. Despite the clear opportunity, the differences in healthcare systems on a country by country basis have made execution of strategies challenging.

Table Of Contents

Table Of Contents

1. Executive Summary
2. The Big Picture: Industry Transition
3. Competitor Landscape
4. Challenges and Strategies
5. Technology Trends and Future Market Directions
6. Critical Country Analysis
7. Final Thoughts
8. The Frost and Sullivan Story

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

2014 Market Segmentation Analysis of the Global Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations

2014 Market Segmentation Analysis of the Global Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations

  • $ 34 500
  • Industry report
  • July 2014
  • by Venture Planning Group

Complete report $34,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Future Horizons and Growth Strategies in the Global Microbiology Testing Market 2014: Supplier Shares and Country Forecasts

Future Horizons and Growth Strategies in the Global Microbiology Testing Market 2014: Supplier Shares and Country Forecasts

  • $ 21 100
  • Industry report
  • August 2014
  • by Venture Planning Group

Complete report $32,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. “2014 Strategies for the Global Microbiology Testing Market” is a new seven-country strategic analysis ...

The 2014 World%s Leading Diagnostic Imaging Companies

The 2014 World%s Leading Diagnostic Imaging Companies

  • $ 14 500
  • Industry report
  • August 2014
  • by Venture Planning Group

Complete report $14,500.  Individual company assessments $2,450.  The report is available by company, section, market segment, and can be custom-tailored to your specific information needs and budget. ...

Global Wound Care Market Outlook

October 2014 $ 8 000

1 Companies

Company Profiles

Lumedx Corp.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.